Ну красота же:
Цитата:
For persons with type 1 diabetes, the mean difference in HbA1c level between short-acting insulin analogues and regular human insulin was −0.15% (CI, −0.20% to −0.10%) (low-quality evidence). Long-acting insulin analogues and human NPH insulin had similar effects on HbA1c level (moderate-quality evidence). Both detemir and glargine reduced risk for severe hypoglycemia, but only the reduction with detemir was statistically significant (moderate-quality evidence). Data on other critical and important outcomes were not available.
|
И про таблетки примерно в том же ключе, а GLP-миметики вообще не рассматривались.
Как по мне, на конгрессе надо отдельную секцию выделить под разбор документа. И целиком внести в "Алгоритмы..." - отдельной главой.